Publications by authors named "R Hesselstrand"
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis.
RMD Open
November 2024
Objective: Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs.
Methods: All patients with dcSSc from the large, multicentric, ScleroID cohort were included.
Article Synopsis
- The study aimed to compare bone mineral density (BMD) and osteoporosis rates in systemic sclerosis (SSc) patients to those in a general population, highlighting specific SSc-related factors influencing BMD.
- It involved 211 SSc patients (majority women) and 505 control participants, measuring BMD at the hip and lumbar spine using X-ray technology, with specific criteria for osteopenia and osteoporosis.
- Results showed significantly lower BMD in SSc patients, particularly women, with factors like age, BMI, menopause, and certain SSc symptoms (like finger ulcers) contributing to decreased BMD, highlighting the need for bone health evaluations in all SSc patients.
Article Synopsis
- The study examines the risk of developing cardiac arrhythmia in patients with systemic sclerosis (SSc) over time, investigating possible risk factors and the relationship between arrhythmia and mortality.
- Using Swedish national registers, researchers tracked 1,565 SSc patients and 16,009 matched controls from 2004 to 2019, finding a significantly higher incidence of arrhythmia in SSc patients compared to controls.
- The findings suggest that arrhythmia appears early in the course of SSc and is linked to increased mortality, particularly influenced by factors like male sex, older age, and pulmonary arterial hypertension.
Objective: Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).
Methods: Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later.
Corrigendum to "Incidence and prevalence of systemic sclerosis in Sweden, 2004-2015, a register-based study" [Seminars in Arthritis and Rheumatism 53 (2022), 151978].
Semin Arthritis Rheum
December 2023